메뉴 건너뛰기




Volumn 210, Issue 4, 2013, Pages 655-663

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD4 ANTIBODY; VIRUS ENVELOPE PROTEIN; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

EID: 84878626061     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20122824     Document Type: Article
Times cited : (248)

References (29)
  • 1
    • 56449131391 scopus 로고    scopus 로고
    • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
    • Binley, J.M., E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. http://dx.doi.org/10.1128/JVI.01762-08
    • (2008) J. Virol. , vol.82 , pp. 11651-11668
    • Binley, J.M.1    Lybarger, E.A.2    Crooks, E.T.3    Seaman, M.S.4    Gray, E.5    Davis, K.L.6    Decker, J.M.7    Wycuff, D.8    Harris, L.9    Hawkins, N.10
  • 3
    • 79955389756 scopus 로고    scopus 로고
    • The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
    • CAPRISA002 Study Team
    • Gray, E.S., M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, et al; CAPRISA002 Study Team. 2011a. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11
    • (2011) J. Virol. , vol.85 , pp. 4828-4840
    • Gray, E.S.1    Madiga, M.C.2    Hermanus, T.3    Moore, P.L.4    Wibmer, C.K.5    Tumba, N.L.6    Werner, L.7    Mlisana, K.8    Sibeko, S.9    Williamson, C.10
  • 4
    • 79959301474 scopus 로고    scopus 로고
    • Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study
    • HVTN 503/Phambili study team
    • Gray, G.E., M. Allen, Z. Moodie, G. Churchyard, L.G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M.H. Latka, et al; HVTN 503/Phambili study team. 2011b. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11:507-515. http://dx.doi.org/10.1016/S1473-3099(11)70098-6
    • (2011) Lancet Infect. Dis. , vol.11 , pp. 507-515
    • Gray, G.E.1    Allen, M.2    Moodie, Z.3    Churchyard, G.4    Bekker, L.G.5    Nchabeleng, M.6    Mlisana, K.7    Metch, B.8    de Bruyn, G.9    Latka, M.H.10
  • 6
    • 34247340435 scopus 로고    scopus 로고
    • Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors
    • Horikawa, K., S.W. Martin, S.L. Pogue, K. Silver, K. Peng, K. Takatsu, and C.C. Goodnow. 2007. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J. Exp. Med. 204:759-769. http://dx.doi.org/10.1084/jem.20061923
    • (2007) J. Exp. Med. , vol.204 , pp. 759-769
    • Horikawa, K.1    Martin, S.W.2    Pogue, S.L.3    Silver, K.4    Peng, K.5    Takatsu, K.6    Goodnow, C.C.7
  • 7
    • 80052334922 scopus 로고    scopus 로고
    • RosettaRemodel: a generalized framework for flexible backbone protein design
    • Huang, P.S., Y.E. Ban, F. Richter, I. Andre, R. Vernon, W.R. Schief, and D. Baker. 2011. RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS ONE. 6:e24109. http://dx.doi.org/10.1371/journal.pone.0024109
    • (2011) PLoS ONE. , vol.6
    • Huang, P.S.1    Ban, Y.E.2    Richter, F.3    Andre, I.4    Vernon, R.5    Schief, W.R.6    Baker, D.7
  • 8
    • 84866495323 scopus 로고    scopus 로고
    • Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
    • Kwong, P.D., and J.R. Mascola. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012
    • (2012) Immunity. , vol.37 , pp. 412-425
    • Kwong, P.D.1    Mascola, J.R.2
  • 11
    • 0033942750 scopus 로고    scopus 로고
    • V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
    • Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 74:6769-6776. http://dx.doi.org/10.1128/JVI.74.15.6769-6776.2000
    • (2000) J. Virol. , vol.74 , pp. 6769-6776
    • Ly, A.1    Stamatatos, L.2
  • 13
    • 77952311370 scopus 로고    scopus 로고
    • The role of antibodies in HIV vaccines
    • Mascola, J.R., and D.C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256
    • (2010) Annu. Rev. Immunol. , vol.28 , pp. 413-444
    • Mascola, J.R.1    Montefiori, D.C.2
  • 14
    • 79551518897 scopus 로고    scopus 로고
    • Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    • Mikell, I., D.N. Sather, S.A. Kalams, M. Altfeld, G. Alter, and L. Stamatatos. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251. http://dx.doi.org/10.1371/journal.ppat.1001251
    • (2011) PLoS Pathog. , vol.7
    • Mikell, I.1    Sather, D.N.2    Kalams, S.A.3    Altfeld, M.4    Alter, G.5    Stamatatos, L.6
  • 16
    • 58149487645 scopus 로고    scopus 로고
    • Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    • Sather, D.N., J. Armann, L.K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769. http://dx.doi.org/10.1128/JVI.02036-08
    • (2009) J. Virol. , vol.83 , pp. 757-769
    • Sather, D.N.1    Armann, J.2    Ching, L.K.3    Mavrantoni, A.4    Sellhorn, G.5    Caldwell, Z.6    Yu, X.7    Wood, B.8    Self, S.9    Kalams, S.10    Stamatatos, L.11
  • 17
    • 21644446614 scopus 로고    scopus 로고
    • The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner
    • Saunders, C.J., R.A. McCaffrey, I. Zharkikh, Z. Kraft, S.E. Malenbaum, B. Burke, C. Cheng-Mayer, and L. Stamatatos. 2005. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 79:9069-9080. http://dx.doi.org/10.1128/JVI.79.14.9069-9080.2005
    • (2005) J. Virol. , vol.79 , pp. 9069-9080
    • Saunders, C.J.1    McCaffrey, R.A.2    Zharkikh, I.3    Kraft, Z.4    Malenbaum, S.E.5    Burke, B.6    Cheng-Mayer, C.7    Stamatatos, L.8
  • 19
    • 69549091674 scopus 로고    scopus 로고
    • Challenges for structurebased HIV vaccine design
    • Schief, W.R., Y.E. Ban, and L. Stamatatos. 2009. Challenges for structurebased HIV vaccine design. Curr Opin HIV AIDS. 4:431-440. http://dx.doi.org/10.1097/COH.0b013e32832e6184
    • (2009) Curr Opin HIV AIDS. , vol.4 , pp. 431-440
    • Schief, W.R.1    Ban, Y.E.2    Stamatatos, L.3
  • 20
    • 70649096029 scopus 로고    scopus 로고
    • Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection
    • Sellhorn, G., Z. Caldwell, C. Mineart, and L. Stamatatos. 2009. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine. 28:430-436. http://dx.doi.org/10.1016/j.vaccine.2009.10.028
    • (2009) Vaccine. , vol.28 , pp. 430-436
    • Sellhorn, G.1    Caldwell, Z.2    Mineart, C.3    Stamatatos, L.4
  • 21
    • 84862641275 scopus 로고    scopus 로고
    • HIV vaccine design: the neutralizing antibody conundrum
    • Stamatatos, L. 2012. HIV vaccine design: the neutralizing antibody conundrum. Curr. Opin. Immunol. 24:316-323. http://dx.doi.org/10.1016/j.coi.2012.04.006
    • (2012) Curr. Opin. Immunol. , vol.24 , pp. 316-323
    • Stamatatos, L.1
  • 22
    • 34247392757 scopus 로고    scopus 로고
    • IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta
    • Waisman, A., M. Kraus, J. Seagal, S. Ghosh, D. Melamed, J. Song, Y. Sasaki, S. Classen, C. Lutz, F. Brombacher, et al. 2007. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. J. Exp. Med. 204:747-758. http://dx.doi.org/10.1084/jem.20062024
    • (2007) J. Exp. Med. , vol.204 , pp. 747-758
    • Waisman, A.1    Kraus, M.2    Seagal, J.3    Ghosh, S.4    Melamed, D.5    Song, J.6    Sasaki, Y.7    Classen, S.8    Lutz, C.9    Brombacher, F.10
  • 23
    • 0037147182 scopus 로고    scopus 로고
    • A distinct signaling pathway used by the IgG-containing B cell antigen receptor
    • Wakabayashi, C., T. Adachi, J. Wienands, and T. Tsubata. 2002. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science. 298:2392-2395. http://dx.doi.org/10.1126/science.1076963
    • (2002) Science , vol.298 , pp. 2392-2395
    • Wakabayashi, C.1    Adachi, T.2    Wienands, J.3    Tsubata, T.4
  • 24
    • 84864363185 scopus 로고    scopus 로고
    • Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
    • West, A.P. Jr., R. Diskin, M.C. Nussenzweig, and P.J. Bjorkman. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083-E2090. http://dx.doi.org/10.1073/pnas.1208984109
    • (2012) Proc. Natl. Acad. Sci. USA. , vol.109
    • West Jr., A.P.1    Diskin, R.2    Nussenzweig, M.C.3    Bjorkman, P.J.4
  • 25
    • 77954920017 scopus 로고    scopus 로고
    • Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    • Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. http://dx.doi.org/10.1126/science.1187659
    • (2010) Science. , vol.329 , pp. 856-861
    • Wu, X.1    Yang, Z.Y.2    Li, Y.3    Hogerkorp, C.M.4    Schief, W.R.5    Seaman, M.S.6    Zhou, T.7    Schmidt, S.D.8    Wu, L.9    Xu, L.10
  • 26
    • 80052942203 scopus 로고    scopus 로고
    • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    • NISC Comparative Sequencing Program
    • Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N.S. Longo, M. Louder, K. McKee, et al; NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 333:1593-1602. http://dx.doi.org/10.1126/science.1207532
    • (2011) Science. , vol.333 , pp. 1593-1602
    • Wu, X.1    Zhou, T.2    Zhu, J.3    Zhang, B.4    Georgiev, I.5    Wang, C.6    Chen, X.7    Longo, N.S.8    Louder, M.9    McKee, K.10
  • 27
    • 0027194743 scopus 로고
    • Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
    • Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
    • (1993) J. Virol. , vol.67 , pp. 4557-4565
    • Wyatt, R.1    Sullivan, N.2    Thali, M.3    Repke, H.4    Ho, D.5    Robinson, J.6    Posner, M.7    Sodroski, J.8
  • 28
    • 70449701456 scopus 로고    scopus 로고
    • Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens
    • Xiao, X., W. Chen, Y. Feng, Z. Zhu, P. Prabakaran, Y. Wang, M.Y. Zhang, N.S. Longo, and D.S. Dimitrov. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390: 404-409. http://dx.doi.org/10.1016/j.bbrc.2009.09.029
    • (2009) Biochem. Biophys. Res. Commun. , vol.390 , pp. 404-409
    • Xiao, X.1    Chen, W.2    Feng, Y.3    Zhu, Z.4    Prabakaran, P.5    Wang, Y.6    Zhang, M.Y.7    Longo, N.S.8    Dimitrov, D.S.9
  • 29
    • 77954943648 scopus 로고    scopus 로고
    • Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    • Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819
    • (2010) Science. , vol.329 , pp. 811-817
    • Zhou, T.1    Georgiev, I.2    Wu, X.3    Yang, Z.Y.4    Dai, K.5    Finzi, A.6    Kwon, Y.D.7    Scheid, J.F.8    Shi, W.9    Xu, L.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.